The hindbrain contains critical neurocircuitry responsible for generating defensive 31 physiological responses to hypoglycemia. This counter-regulatory response (CRR) is evoked by local 32 hindbrain cytoglucopenia that causes an autonomically-mediated increase in blood glucose, feeding 33 behavior, and accelerated digestion; that is, actions that restore glucose homeostasis. Recent reports 34 suggest that CRR may be initially triggered by astrocytes in the hindbrain. The present studies in 35 thiobutabarbital-anesthetized rats show that exposure of the fourth ventricle (4V) to 2-deoxyglucose 36 (2DG; 15umol) produced a 35% increase in circulating glucose relative to baseline levels. While the 4V 37 application of the astrocytic signal blocker, fluorocitrate (FC; 5nmol), alone, had no effect on blood 38 glucose levels, 2DG-induced increases in glucose were blocked by 4V FC. The 4V effect of 2DG to 39 increase glycemia was also blocked by the pretreatment with caffeine (non-selective adenosine 40 antagonist) or a potent adenosine A1 antagonist (8-Cyclopentyl-1,3-dipropylxanthine; DPCPX) but not 41 the NMDA antagonist (MK-801). These results suggest that CNS detection of glucopenia is mediated 42 by astrocytes, and that astrocytic release of adenosine that occurs after hypoglycemia may cause the 43 activation of downstream neural circuits that drive CRR. 44 45
Introduction 50 51
Glucose is the primary energy source for cellular metabolism, especially for neurons. Thus, the 52 maintenance of appropriate serum glucose levels is critical for brain function and survival. It is no 53 surprise that there are multiple, overlapping glucoregulatory systems with sensors in the periphery as 54 well as the CNS that function to balance energy influx and energy expenditure as well as caloric 55 regulation, adjustment of metabolic rate, nutrient balance, food preference, and circadian rhythms (6, 56 54, 60, 70, 74) . Glucoprivation triggers defensive physiological and behavioral events that are 57 coordinated through the interplay between central nervous system and peripheral control mechanisms 58 aimed at mobilizing stored carbohydrate during periods of fasting and physiological emergency (20, 59 61) . 60
A critical central nervous system site for the defense against glucopenia is the caudal medulla. 61
This region contains at least two potential detection/ effector control sites: the nucleus of the solitary 62
tract (NST) and the ventrolateral medulla (VLM). Both regions are important to the generation of 63
physiological and behavioral responses to hypoglycemia (1, 46, 61) . These defensive counter-64 regulatory responses (CRR) include increases in serum glucagon and corticosteroids, increased food 65 intake, an increase in adrenergic tone, and a dramatic acceleration in gastric motility (9, 18, 36, 67) . 66
This complex response (CRR) is produced by "protected" circuitry that can function to mobilize 67 glucose and drive feeding behavior in an emergency without significant modulation of, or by, other 68 homeostatic systems. For example, glucoprivic feeding can be elicited even in animals receiving large 69 chronic doses of leptin, i.e., a situation signaling extreme metabolic repletion (76). On the other hand, 70 destruction of medullary neurons critical to the expression of CRR does not significantly affect daily 71 feeding behavior (38) . The advantage of such a system in the management of a physiological 72 emergency is that it retains its sensitivity to the defended parameter under practically all other 73 physiological circumstances (20, 51, 61, 74) This exclusivity of CRR circuitry can help identify CRR vs 74 non-CRR metabolic and feeding control elements. CRR circuit elements are probably not affected by, 75 for example, leptin or α-melanocyte-stimulating hormone (α-MSH) inputs, while non-CRR regulatory 76 feeding and metabolic control elements are biased in their response to glucoprivic stimuli in the 77 presence of signals corresponding to repletion state (20, 51, 61, 74) 78
Recent data from our laboratory as well as others (36, 45, 47, 49) suggest that detection of a 79 low glucose state by brainstem astrocytes could be the trigger to the initiation of CRR. For example, 80
Materials and Methods 113
All experimental procedures were conducted with the approval of the Pennington Biomedical 114
Research Center's Institutional Animal Care and Use Committee and were performed according to the 115 guidelines set forth by the National Institutes of Health. Long Evans rats of either sex (females = 26; 116 males = 28; body weight between 250-450g; age range 4-6months) obtained from the Pennington 117
Biomedical Research breeding colony were used in these studies. Animals were housed in a 118 temperature controlled room under 12hr light/dark cycle and provided water and food ad libitum. 119
Animals were deeply anesthetized with thiobutabarbital (Inactin @ ;Sigma-Aldrich;150 mg/kg, ip; 120 long-term anesthesia with minimal interference on autonomic reflexes (7)) and secured in a stereotaxic 121 frame. Using aseptic technique, the floor of the fourth ventricle (4V) was exposed by removing the 122 occipital skull plate and opening the foramen magnum; dura and arachnoid layers were retracted. 123
Once all preparatory surgery was complete, systemic glucose levels were monitored via blood samples 124 obtained by tail-vein punctures every 30 minutes. Glucose concentrations of the 3-4uL blood droplets 125
were determined with Freestyle Lite glucose test strips and glucometer (Abbott Diabetes Care Inc., 126 Alameda, CA). To ensure that baseline blood glucose levels were stable, samples were taken at 0, 30, 127 and 60min after all preparatory surgery was complete. At the 60min point, each animal was exposed to 128 one of the following 4V experimental conditions: 129
• control: 10uL of either (n = 5) saline or (n = 5) 1:4 DMSO/saline (i.e., vehicle for MK-801, 130 caffeine, or DPCPX); total n = 10, 131
• fluorocitrate (FC; astrocytic metabotropic signal blocker, Sigma Aldrich, St Louis MO), alone 132 (5nanomole in 10uL; (21, 33, 43, 68) ); n = 5, 133
• 2-deoxyglucose (2DG; Sigma Aldrich), alone (18umol in10uL;(14, 36)); n = 6 134
• FC followed 30min later by 2DG (FC+2DG); n = 5, 135
• Caffeine alone (non-selective adenosine receptor antagonist, Sigma; 130nanomol in 6uL (59)); 136 n = 5, 137
• Caffeine followed 30min later by 2DG (caffeine+2DG); n = 5, 138
• A1 specific adenosine antagonist: 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX, Sigma; 139 2nanomole in 2uL (41)) followed 30min later by 2DG (DPCPX+2DG); n = 5, 140
• MK801 (non-specific NMDA antagonist, Sigma; 18nanomol in 10uL (12)) followed 30min later 141 by 2DG (MK801+2DG); n = 5 142
143
Although other, previous studies of central 2DG effects have used awake rats equipped with 144 chronic ventricular cannulas to deliver the challenge (15, 77), we chose instead to use thiobutabarbital-145 anesthetized rats and direct application of agents to the floor of the fourth ventricle to match our recent 146 physiological studies of hindbrain 2DG cytoglucopenia effects on gastric motility and gastric vago-vagal 147 reflex circuitry (36). Additionally, we used the same amount of 2DG in both the motility (36) and these 148 blood glucose studies (i.e., 3mg = 18umol). This amount of centrally administered 2DG is a fraction of 149 that used in previous awake studies (i.e., (15, 77) . 150
The "1:4 DMSO/saline" group served as a control for both those groups that required the partial 151 DMSO solution as a vehicle (i.e., MK-801, caffeine, or DPCPX) as well as a control for the osmolality 152 challenge of 2DG alone. Baseline levels of blood glucose (mg/dL) within each group were averaged 153 and compared in a one way analysis of variance ( Figure 1) . 154
Blood glucose levels were monitored every 30min for a minimum of 180min. Kinetics of the 155 glycemic responses are shown in Figure 2 . For statistical analysis, changes in blood glucose levels 156 were expressed as percent changes relative to baseline for each individual animal. Thus, each animal 157 served as its own control. These normalized values of maximal percent change in blood glucose levels 158 for each group were averaged and subjected to a one way analysis of variance followed by Dunnett's 159 post-hoc tests for statistical significance (P < 0.05). 160
In a subset of rats (N = 4 males, 4 females), all preparations were as described above including 161 anesthesia and open cranium. The hindbrain was treated either with saline or FC; the 2DG challenge 162 (100mg/kg/ml; typical volume ~0.3ml) was delivered subcutaneously 30min after either hindbrain 163 treatment. This dose of 2DG provides the lowest level of systemic glucoprivic challenge that still 164 produces a significant increase in counter-regulatory hyperglycemia (66). Blood glucose levels were 165 monitored and normalized as described above. The maximal percent change in blood glucose levels for 166 either group was averaged and subjected to an unpaired Student's t-test for statistical comparison 167 (significance = P < 0.05). 168
169

Results
170
Individual baseline blood glucose levels ranged from 70-95mg/dL (overall average + SEM = 171 80.3+ 0.8mg/dL; Fig. 1 ) in these non-deprived, anesthetized rats. There were no significant differences 172 in baseline levels across the experimental groups (ANOVA F 8,45 = 1.71; p = 0.34). 173
Similar to previous reports on the glucoprivic effects of 2DG to elicit elevations in blood glucose 174 levels (15, 20, 38, 62, 74, 77) , exposure of the dorsal medulla to 18umole 2DG produced significantelevations (% change) in blood glucose levels relative to baseline levels starting within 90min of the 176 challenge ( Fig. 2A ) and peaking at approximately 150min after 4V application. Maximal percent change 177 in blood glucose levels were determined for each animal based on their individual baseline and peak 178 responses. Maximal peak responses for the 2DG alone group averaged 36.0 + 7.4% change (Fig.3) . 179
Fourth ventricular application of vehicle controls (saline or 1:4 DMSO/saline), FC alone, or 180 caffeine alone, had no effect on glucose levels ( Fig. 2B and 3) . However, pretreatment of the fourth 181 ventricle with FC blocked the effect of subsequent 2DG to increase blood glucose (FC+2DG: 3.1 + 182 2.0%; Fig. 2A and 3) . Similarly, pretreatment with the adenosine antagonists, caffeine and DPCPX, 183 suppressed the glycemic effects of 2DG (caffeine+2DG = 5.7 + 2.8%; DPCPX+2DG = 11.1 + 2.4%; Fig.  184 2C and 3). In contrast, the NMDA antagonist, MK801, did not block the 2DG effect to increase blood 185 glucose (MK801+2DG = 22.2 + 6.4% change relative to baseline; Fig. 2C and 3) . One way ANOVA 186 F 7,38 = 9.78, p < 0.0001; Dunnett's post-hoc test * p < 0.05. 187
Subcutaneous 2DG (100mg/kg/ml) elicited increased blood glucose levels ( Our data show that 4V exposure to 2DG in thiobutabarbital-anesthetized rats can elicit the 194 expected elevation in blood glucose of CRR as has been previously reported in response to intracranial 195 or peripheral challenges in the awake animal (15, 20, 38, 62, 74, 77) . This centrally-induced CRR effect 196 on glycemia was blocked by exposure of the 4V to fluorocitrate, a selective blocker of astrocyte 197 metabotropic signaling and gliotransmission (71). Thus, these data are consistent with the hypothesis 198 that hindbrain astrocytes are important components of CNS glucodetection circuits that drive multiple 199 aspects of CRR (36, 45, 47) . Further, the 4V application of adenosine receptor antagonists (caffeine 200 and the A1 antagonist, DPCPX) also suppressed the hindbrain 2DG effect to initiate CRR. This is in 201 contrast to the lack of effect of the NMDA antagonist (MK801) to suppress the 2DG evoked increase in 202 glycemia. These data suggest that astrocytes are important sensors of low glucose availability (central 203 2DG-induced glycemia). Recall that NMDA receptors on neurons carry the inward current generated by will form what has been termed the "tripartite synapse" (4, 11, 31, 32, 57) in which presynaptic 214 terminals and synaptic efficacy are regulated by astrocytes as well as the post-synaptic responsiveness 215 to afferent input and neuronal excitability. Astrocytes are, themselves, subject to modulation by most of 216 the "classic" neurotransmitters (e.g., glutamate, norepinephrine) that are released from neuronal 217 presynaptic terminals (34, 48, 71) 
as well as gliotransmitters released by other astrocytes (30). 218
Additionally, hormones, circulating factors such as thrombin, changes in endogenous physiological 219 signals such as O 2 /CO 2 or pH, and changes (particularly, reductions) in glucose concentration or 220 metabolic availability can all increase astrocytic calcium levels (3, 5, 26, 29, 35, 39, 47) . This increase 221 in astrocytic calcium is coupled to a release of gliotransmitters in processes similar to 222 neurotransmission (31, 32, 57, 79). Glutamate, ATP, adenosine, and D-serine are among the agents 223 now accepted as gliotransmitters (2, 5, 17, 23, 44, 55) . 224
The astrocytic release of adenosine may be especially relevant to the connection between 225 astrocytic glucodetection and the activation of downstream CRR mechanisms. There is good evidence 226 that adenosine is released rapidly within the CNS in response to glucoprivation (69). A number of 227 downstream effects of CNS hypoglycemia are known to be blocked by antagonists to the A1 adenosine 228 receptor (52, 69). There are at least two mechanisms by which astrocytes subjected to hypoglycemia 229 could increase the adenosine concentration in the vicinity of neurons. First, adenosine can be released 230 directly from astrocytes through reversible equilibrating nucleoside transporters in the cell membrane 231 (50); a release that is not coupled to cytoplasmic calcium. This would occur as a consequence of the 232 exhaustion of cytoplasmic ATP and the build-up of adenosine. Second, ATP released by calcium 233 dependent gliotransmission after detection of low extracellular glucose is readily converted to 234 adenosine via the action of ectonucleotidases (4, 40). This sort of astrocyte purinergic gliotransmission 235 has already been implicated in chemoreflex regulation of respiration (22). Adenosine release from 236 astrocytes in response to metabolic stress is well-documented. However, the mechanism connecting 237 adenosine release, ATP catabolism, and astrocyte calcium signaling remains controversial (43). While 238 glucopenia-driven adenosine release from neurons might also occur, if that neuronal source were the 239 predominant mechanism for the subsequent CRR response, then the astrocyte metabolic blocker, FC, 240
should not have had the effect to block 2DG-induced increases in blood glucose. 241
Adenosine acting on the A1 receptor typically causes neuronal inhibition (24, 64) . Such 242 inhibition of neuronal activity would explain our observations on glucoprivation effects on gastric vago-243 vagal control of motility. Glucoprivation causes a dramatic increase in gastric motility (9, 13, 14, 36) . 244
This effect on gastric motility is dependent on intact astrocyte signaling (36). Glucoprivic stimuli (e.g., 245 2DG) cause NST neurons to be less excitable and less excited by vagal afferent inputs from the gut. 246
NST neurons receiving vagal afferent inputs from the gut, in turn, powerfully inhibit neurons in the DMN 247 that are responsible for activating gastric motility (36, 63). Therefore, it is possible that adenosine 248 release from glucosensitive astrocytes could be responsible for the inhibition of gastric vagal NST 249 neurons and the consequent increase in DMN-mediated gastric motility. Further, it is also possible that 250 adenosine inhibition of NST neurons could also release ventrolateral medullary neurons from tonic 251 inhibition, thus increasing downstream sympathetic activity. These medullary neurons are well known 252 to be involved in the control of sympathetic activity that impinges on cardiovascular as well as glycemic 253
control (61, 72) . 254
The attribution of these glucoprivic sensing effects on astrocytes is due to the specificity of 255 fluorocitrate (FC) to suppress astrocytic function. Although high doses (micromolar amounts) of FC can 256 derange astrocyte mitochondrial function and have secondary repercussions for neuronal activity (e.g., 257
resulting in seizures or death as a result of the withdrawal of the stabilizing influences of glia over 258 neuronal excitability (27, 37, 58)), nanomolar amounts (as used in our studies) are astrocyte specific 259 and entirely reversible (16, 71) . The specificity of action of FC in glial cells is supported by several, now 260 classic, biochemical observations. First, glial cells avidly take up and metabolize FC, while neurons do 261 not (16, 53) . FC is an aconitase inhibitor (16); the metabolic result of which is rapid accumulation of 262 citrate. This effect is not observed in neurons (75). Furthermore, in live cell imaging studies, we have 263
shown that nanomolar doses of FC: a) only inhibits astrocytes, b) specifically inhibits metabotropic and 264 not ionotropic pathways of astrocytes, and c) is reversed within minutes of washout (71). 265
Mechanistic explanations of FC-astrocyte inhibition are rooted in classic biochemical studies 266 (16, 42). Buffa and Peters (8) were among the first to observe the metabolic overflow of citrate 267 following FC exposure. Citrate is a potent cation chelator and these early authors postulated that an 268 overflow of citrate would disturb cellular excitability through the inactivation of calcium. This theory 269 obtained currency with the observation that FC effects can be mimicked by the application of calcium 270 chelators which are, themselves, buffered by the co-application of excess calcium (37). It is now 271 believed that the FC-induced increase in intracellular citrate produces a buffering of calcium, as well as 272 magnesium and manganese ions. This effect may be responsible for not only the elimination of 273 calcium-dependent gliotransmisson but also for the blockade of glia-specific metabolic pathways 274 dependent on these cations (16, 25, 42, 56) . 275 276
Perspectives and Significance 277
The present study suggests that astrocytes are important sensors of low glucose availability. In 278 turn, astrocytes are probably signaling this "hypoglycemic condition" to appropriate neurons in the 279 hindbrain neurocircuitry involved in CRR reflexes via purinergic agonists such as adenosine. Together, 280 these data suggest that astrocytes in the hindbrain are not only necessary for the detection of hindbrain 281 cytoglucopenia but are also important for the accurate integration of cytoglucopenia information from 282 the periphery. 283
There is now good evidence that astrocytes in the NST and other circumventricular regions 284 perform important functions as chemosensors. NST astrocytes have been suspected of having a 285 sensitivity to acute glucoprivation (78). This concept was supported by the work of Marty et al (45, 46) solutes and exert early influence on adjacent neural systems dedicated to homeostatic regulation of 296 these agents (19) . In addition to the counter-regulatory control of glucose homeostasis, glial cells have 297 also been identified as critical detectors of pCO 2 for respiratory control by the ventral medulla (28), and 298 sodium ions for salt intake control by the subfornical organ (65, 73) . Evidence is accumulating that glia 299 may be important for the detection of different sensory modalities (e.g., pCO 2 , pH, blood glucose levels) 300 Maximal percent change in blood glucose levels relative to baseline levels were averaged within each 343 group. Maximal peak responses for the 2DG (alone) group averaged 36.0 + 7.4% change. While 4V 344 application of vehicle controls (saline or 1:4 DMSO/saline) or FC (alone) or caffeine (alone; data shown 345 in Fig 2B) had no effect on glucose levels, pretreatment of the 4V with FC blocked the effect of 346 subsequent 2DG to increase blood glucose (FC+2DG: 3.1 + 2.0%). Similarly, pretreatment with 347 caffeine or DPCPX suppressed the glycemic effects of 2DG (caffeine+2DG = 5.7 + 2.8%; DPCPX+2DG 348 = 11.1 + 2.4%). In contrast, the NMDA antagonist, MK801, did not block the 2DG effect to increase 349 blood glucose (MK801+2DG = 22.2 + 6.4%). One way ANOVA F 7,38 = 9.78, p < 0.0001; Dunnett's post-350 hoc test * p < 0.05. 
